Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mentor

This article was originally published in The Gray Sheet

Executive Summary

Final module of a silicone gel-filled breast implant PMA application is filed with FDA. Advisory panel review is likely, the firm says (1"The Gray Sheet" Nov. 3, 2003, p. 22). Competitor Inamed received panel endorsement of its PMA Oct. 15 (2"The Gray Sheet" Oct. 20, 2003, p. 3)...

You may also be interested in...



Mentor Brachy Sales May Rise With ASC Code; Firm Seeds Women’s Health

Mentor contends that the addition of prostate brachytherapy to the list of ASC covered services, combined with resolution of the firm's supply problems, will boost Q3 sales for the segment

Inamed Silicone Implant Patient Monitoring Plans Allay Rupture Concerns

Inamed's proposal to closely follow patients implanted with silicone gel-filled breast prostheses helped sway FDA's General & Plastic Surgery Devices Panel to recommend conditional approval of the firm's PMA by a 9-6 margin

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel